Company Overview and News

 
Teva Pharm says FDA to decide on migraine drug on Sept 16

19h reuters
JERUSALEM (Reuters) - Israeli drugmaker Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as early as mid-September, after an initial delay.

 
Teva Pharm says FDA to decide on migraine drug on September 16

19h channelnewsasia
Israeli drugmaker Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as early as mid-September, after an initial delay.

 
Valeant: The Xifaxan Killer Could Arrive In November

20h seekingalpha
Cosmo Pharmaceuticals announced that the FDA has set a PDUFA date of November 16, 2018, to decide on its NDA for Rifamycin.

 
Warren Buffett Loves TEVA Stock and You Should Too

2018-05-23 investorplace
While Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE:TEVA) faded from last Wednesday highs, shares ultimately climbed about 3% that day. No, it wasn’t earnings or a new drug that gave TEVA stock a bump. Instead, it was Warren Buffett.

 
Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod

2018-05-21 zacks
Migraine is a serious neurological disease, which has significant effects on patients’ daily life. Patients suffer from debilitating pain and physical impairment along with fear of the next attack. It is estimated that patients with frequent migraine attacks may lose more than half of their life to the disease.

 
Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data

2018-05-21 seekingalpha
Rocket Pharma’s gene therapy drug RP-L102 showed treatment benefit in an early stage study in Fanconi anemia.

1
Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

2018-05-18 zacks
This week AstraZeneca (AZN - Free Report) , Novartis (NVS - Free Report) and Eli Lilly (LLY - Free Report) announced regulatory and pipeline updates on line extensions of their marketed drugs. While AstraZeneca’s asthma drug Fasenra failed to meet the primary endpoint in a late-stage study evaluating it for an expanded indication — chronic obstructive pulmonary disease (“COPD”); Lilly’s migraine candidate galcanezumab met the same in a late-stage study, evaluating it for another indication — prevention of episodic cluster headache.

 
Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up

2018-05-18 zacks
Amgen (AMGN - Free Report) and partner Novartis (NVS - Free Report) announced that the FDA has approved their pipeline candidate Aimovig (erenumab) for the prevention of migraine.

 
Amgen, Novartis Set to Launch Migraine Drug Aimovig Next Week after FDA Approval

2018-05-18 genengnews
Amgen and Novartis are set to commercially launch the migraine prevention treatment Aimovig™ (erenumab)in the U.S. next week--the first calcitonin gene-related peptide (CGRP) receptor inhibitor approved by the FDA.

 
Amgen’s Novel Migraine Treatment Gets Key Approval

2018-05-18 247wallst
Amgen Inc. (NASDAQ: AMGN) shares saw a nice bump after the U.S. Food and Drug Administration (FDA) on Thursday approved Aimovig (erenumab), Amgen’s preventive treatment of migraine in adults. It is the first FDA-approved preventive migraine treatment in a new class of drugs, which work by blocking the activity of calcitonin gene-related peptide, which is believed to play a critical role in migraine attacks.

7
Tracking George Soros' Portfolio - Q1 2018 Update

2018-05-17 seekingalpha
Soros' 13F portfolio value increased from $4.37B to $6.16B this quarter. The number of positions increased from 196 to 219.

 
Teva's Generic Restasis Could Punish Allergan

2018-05-17 seekingalpha
AGN's Restasis receives about 4% of its revenue from Canada. Q1 2018 Restasis revenue fell 15% Y/Y.

2
Berkshire doubles Teva stake, adds to Apple, ends a newspaper bet

2018-05-16 channelnewsasia
Warren Buffett's Berkshire Hathaway Inc on Tuesday said it has more than doubled its investment in generic drugmaker Teva Pharmaceutical Industries Ltd , and confirmed it has become Apple Inc's second-largest shareholder.

 
Teva Pharmaceutical Industries Ltd, Once a Falling Machete, Is Spiking -- Chase It | InvestorPlace

2018-05-16 investorplace
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock has been decimated over the years. It fell 75% off the highs of 2015. This morning the stock is rallying on the news that the famed investor Warren Buffett doubled his stake in Teva stock.

 
Eli Lilly's Cluster Headache Candidate Succeeds in Phase III

2018-05-16 zacks
Eli Lilly & Company’s (LLY - Free Report) pipeline candidate, galcanezumab met its primary as well as secondary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.

TEVA : Teva Pharmaceutical Industries Stock Analysis and Research Report

2017-10-24 - Asif

Teva Pharmaceutical Industries is global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic medicines and a focused portfolio of specialty medicines. The company operate worldwide, with a significant presence in the United States, Europe and many other markets around the world. Its key strengths include itsworld-leading generics expertise and portfolio, focused specialty portfolio, robust R&D capabilities, global infrastructure and scale and dedicated leadership and employees. Teva Pharmaceutical believe company is strategically positioned to benefit from market, economic and regulatory trends in global healthcare. These trends include aging populations, the increasing prevalence of chronic diseases, economic pressure on governments and private payors to provide affordable healthcare solutions, legislative and regulatory reforms, scientific and technological advances, increased patient awareness...

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 881624209